Picture this: A cancer patient in a district hospital, once sent abroad for care, now begins treatment with cell therapy—developed and produced just a few hours away, in a domestic biomanufacturing facility. No loud declarations, no sweeping claims–just the quiet signal of a new capability taking root, as India steadily builds a biomanufacturing future from the ground up. Health care. (Photo:Fortis Healthcare) India’s strength in pharmaceuticals is well known–but what’s unfolding now goes beyond low-cost generics and vaccines. With promising advances like the recent approval of India’s first indigenous CAR-T cell therapy and successful early-stage gene therapy trials for haemophilia, India is carving out a leadership role on the global stage of biologics. But seizing this opportunity is not guaranteed. It depends on how we build the path ahead. India has the ingredients—future-ready talent base, manufacturing infrastructure, and supportive government initiatives like the Production Linked Incentives and the BioE3 policy. These have laid the foundation, but rising as a leader will demand more: coordination, bold investment, and a focus on capabilities that secure long-term advantage. …